FDA panel considers an injectable drug that prevents RSV in infants

An independent advisory committee to the Food and Drug Administration will decide Thursday whether to recommend an injectable drug that can protect infants up to 2 years old from RSV. Respiratory syncytial virus causes lower respiratory illness and is most severe for older adults and babies under…

#rsv #oferlevy #beyfortus #unitedkingdom #astrazeneca #sanofi #fda #synagis #pfizer